These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21345281)

  • 1. High hopes for RANKL: will the mouse model live up to its promise?
    Tanos T; Brisken C
    Breast Cancer Res; 2011 Jan; 13(1):302. PubMed ID: 21345281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
    Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
    Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A local basis for progesterone action during mammary tumorigenesis - no longer RANK and file.
    Petrie WK; Hovey RC
    Breast Cancer Res; 2011 Jan; 13(1):301. PubMed ID: 21345282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
    Schramek D; Leibbrandt A; Sigl V; Kenner L; Pospisilik JA; Lee HJ; Hanada R; Joshi PA; Aliprantis A; Glimcher L; Pasparakis M; Khokha R; Ormandy CJ; Widschwendter M; Schett G; Penninger JM
    Nature; 2010 Nov; 468(7320):98-102. PubMed ID: 20881962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone/RANKL is a major regulatory axis in the human breast.
    Tanos T; Sflomos G; Echeverria PC; Ayyanan A; Gutierrez M; Delaloye JF; Raffoul W; Fiche M; Dougall W; Schneider P; Yalcin-Ozuysal O; Brisken C
    Sci Transl Med; 2013 Apr; 5(182):182ra55. PubMed ID: 23616122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From the ranks of mammary progesterone mediators, RANKL takes the spotlight.
    Fernandez-Valdivia R; Lydon JP
    Mol Cell Endocrinol; 2012 Jun; 357(1-2):91-100. PubMed ID: 21964466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biology of progesterone receptor in the normal mammary gland and in breast cancer.
    Obr AE; Edwards DP
    Mol Cell Endocrinol; 2012 Jun; 357(1-2):4-17. PubMed ID: 22193050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL inhibition: a promising novel strategy for breast cancer treatment.
    González-Suárez E
    Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
    Kotsopoulos J; Singer C; Narod SA
    Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Selective Progesterone Receptor Modulators and Their Impact on the RANK/RANKL Complex Activity.
    Błaszczak-Świątkiewicz K
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32183159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From bone to breast and back - the bone cytokine RANKL and breast cancer.
    Hofbauer LC; Rachner TD; Hamann C
    Breast Cancer Res; 2011 May; 13(3):107. PubMed ID: 21635706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL/RANK - from bone physiology to breast cancer.
    Sigl V; Penninger JM
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
    Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
    Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL/RANK: from bone loss to the prevention of breast cancer.
    Sigl V; Jones LP; Penninger JM
    Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RANKL-RANK Story.
    Nagy V; Penninger JM
    Gerontology; 2015; 61(6):534-42. PubMed ID: 25720990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.
    van de Ven M; Liu X; van der Burg E; Klarenbeek S; Alexi X; Zwart W; Dijcks F; Bouwman P; Jonkers J
    J Pathol; 2018 Sep; 246(1):41-53. PubMed ID: 29877575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.